Development and validation of a psoriasis treatment acceptability measure through group concept mapping.
Authors: Stacie Hudgens, Amy Howerter, Shannon Keith, Colby Evans, Corey Pelletier
DOI: 10.1186/s12955-023-02162-6
Publication Summary
The scientific publication, "Development and validation of a psoriasis treatment acceptability measure through group concept mapping," dated 08 August 2023, underscores a groundbreaking initiative to foster a more patient-centric model in evaluating psoriasis treatments. The study meticulously developed and validated a novel measure using the robust methodological framework of group concept mapping (GCM). This initiative spearheads a more nuanced understanding of treatment acceptability, encompassing various facets such as ease of administration, side effects, and cost, thereby marking a significant stride toward optimizing clinical outcomes for individuals with psoriasis.
Professional Blog
In psoriasis treatment, the quest for efficacy has always been paramount. However, the narrative is gradually shifting to embrace a broader spectrum of treatment evaluation, primarily focusing on treatment acceptability from a patient's perspective. The publication "Development and validation of a psoriasis treatment acceptability measure through group concept mapping" heralds a significant advancement in this direction.
Together we can find a cure. Will you help? Donate today.
Each year 20,000 children under 10 years old are diagnosed with psoriasis, and sadly, many endure bullying. Your gift helps fund research that leads to improved treatments that can lessen or eliminate symptoms for kids, and one day, we will get to a cure together. Will you help?
The journey toward developing and validating the Psoriasis Treatment Acceptability Measure (PTAM) was anchored on the robust Group Concept Mapping (GCM) methodology. This collaborative approach, involving patients, healthcare providers, and other stakeholders, facilitated a holistic examination of treatment acceptability. The endeavor culminated in the birth of a comprehensive measure capable of encapsulating the multifarious dimensions of treatment acceptability.
The PTAM, as unveiled in this seminal work, embodies a paradigm shift in psoriasis treatment evaluation. It echoes a resounding emphasis on patient-centric approaches, heralding a new era where treatment assessments resonate with individuals' experiences and preferences grappling with psoriasis. The implications of PTAM stretch beyond just a measure; it's a bold step toward redefining treatment evaluation, potentially catalyzing enhancements in patient satisfaction and treatment adherence.
This publication aligns with the core ethos of Clinical Outcomes Solutions. It propels the scientific community closer to a future where treatment evaluations reflect the patient's needs and preferences. The ripple effects of this pioneering work are expected to be far-reaching, nudging the realms of clinical practice and health policy discourse toward a more holistic and patient-centric model.
Call to Action
The Psoriasis Treatment Acceptability Measure (PTAM) unveils the boundless possibilities in the synergy of collaborative efforts, rigorous scientific methodologies, and a staunch commitment to patient-centric care. At Clinical Outcomes Solutions, we are poised at the cusp of this exciting scientific innovation, ready to delve deeper and contribute to the evolving narrative of psoriasis treatment evaluation.
We invite the scientific community, healthcare professionals, and stakeholders to engage with this seminal work, reflect on its implications, and propel the discourse forward. Explore the complete publication and join us in this exciting venture towards fostering superior clinical outcomes and enhancing the quality of life for individuals with psoriasis. Together, let’s champion a future of healthcare that is as multifaceted and inclusive as the individuals it seeks to serve.